Medicenna Therapeutics Corp. MDNAF
Set alert
0.32 USD -0.03 -8.05%
At close · Oct 30
0.32 Day range 0.33
0.229 52-week range 1.30
- YTD
- -52.66%
- 1 year
- -69.52%
- Open
- 0.33
- Prev close
- 0.348
- Mkt cap
- 29.54M
- Vol
- 7.50K
- Avg vol
- 44.05K
- EPS
- -0.16
- P/E
- 0.00
More statistics
- Low
- 0.32
- High
- 0.33
3M chart
Signals (26)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 27, 2026 | 6 days ago |
| SMA: Bearish | Oct 26, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 26, 2026 | 1 week ago |
| SMA: Bullish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| SMA: Bearish | Oct 19, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 14, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 6, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| RSI: Overbought | Aug 26, 2026 | 2 months ago |
| RSI: Overbought | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
Financials — quick view
MDNAF Revenue — quarterly 0
MDNAF Net income — quarterly -2.86M
MDNAF EPS — quarterly -0.04
News
- Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
- Medicenna Announces Results of Annual General and Special Meeting of Shareholders
- Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
- Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
- Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
- Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
- Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
- Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
- Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
- Medicenna Announces the Launch of a Marketed Public Offering of Securities
Your note
Sign in to keep a note on MDNAF — it syncs with the Stock Master app.